Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis

被引:51
作者
Hwang, SA
Kruzel, ML
Actor, JK
机构
[1] Univ Texas, Hlth Sci Ctr, Sch Med, Dept Pathol & Lab Med,Program Mol Pathol, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77030 USA
关键词
lactoferrin; BCG vaccine efficacy; Mycobacterium tuberculosis;
D O I
10.1016/j.intimp.2004.11.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The ability to control intracellular Mycobacterium tuberculosis (MTB) infection relies on cellular immunity and generation of a strong T-cell helper 1 (T(H)1 response. Lactoferrin, an iron-binding protein with immune regulatory functions, was investigated as an adjuvant to boost Mycobacterium bovis Bacillus Calmette-Guerin (BCG) efficacy. Lactoferrin was initially shown to augment IL-12(p40) production from macrophages stimulated with LPS. A single immunization of mice with Lactoferrin as an adjunct adjuvant resulted in amplified splenocyte proliferative response to heat-killed BCG, and elevated IL12(p40) production with increased relative ratios of IL-12/IL-10. Furthermore, splenocyte recall response to HK-BCG was augmented for proinflammatory mediators, TNF-alpha, IL-1beta, and IL-6, approaching responses generated to complete Freund's adjuvant (CFA) immunized controls. Specific responses were identified, with significant elevation of IFN-gamma generated during antigenic recall. Subsequent aerosol challenge of Lactoferrin adjuvant immunized mice with virulent M. tuberculosis revealed decreased mycobacterial loads in the lung, and limitation of organism dissemination to a peripheral organ (spleen). These studies indicate that Lactoferrin can act as an adjunct adjuvant to augment cellular immunity and boost BCG efficacy for protection against subsequent challenge with virulent MTB. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 29 条
[1]   Lactoferrin immunomodulation of DTH response in mice [J].
Actor, JK ;
Hwang, SA ;
Olsen, M ;
Zimecki, M ;
Hunter, RL ;
Kruzel, ML .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (04) :475-486
[2]   A role for complement C5 in organism containment and granulomatous response during murine tuberculosis [J].
Actor, JK ;
Breij, E ;
Wetsel, RA ;
Hoffmann, H ;
Hunter, RL ;
Jagannath, C .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 53 (05) :464-474
[3]  
Adamik Barbara, 1998, Archivum Immunologiae et Therapiae Experimentalis, V46, P169
[4]   EXPERIMENTAL APPROACHES TO MECHANISMS OF PROTECTION AND PATHOGENESIS IN M. TUBERCULOSIS INFECTION [J].
BLOOM, BR ;
FLYNN, J ;
MCDONOUGH, K ;
KRESS, Y ;
CHAN, J .
IMMUNOBIOLOGY, 1994, 191 (4-5) :526-536
[5]  
Brennan MJ, 2004, PAHO SCI P, P177
[6]   EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE [J].
COLDITZ, GA ;
BREWER, TF ;
BERKEY, CS ;
WILSON, ME ;
BURDICK, E ;
FINEBERG, HV ;
MOSTELLER, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :698-702
[7]   New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex [J].
Collins, DM .
IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (04) :342-348
[8]  
Collins H L, 2001, Lancet Infect Dis, V1, P21, DOI 10.1016/S1473-3099(01)00018-4
[9]   Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present [J].
Cooper, AM ;
Kipnis, A ;
Turner, J ;
Magram, J ;
Ferrante, J ;
Orme, IM .
JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1322-1327
[10]   Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis [J].
Cooper, AM ;
Magram, J ;
Ferrante, J ;
Orme, IM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :39-45